BioNTech tests new TB vaccines in first human safety trial
NCT ID NCT05537038
Summary
This early-stage trial tested the safety of two new tuberculosis vaccine candidates in healthy adults who had never received the standard BCG vaccine. Researchers gave 120 participants different dose levels of the experimental vaccines or a placebo to check for side effects and immune responses. The main goal was to find safe dose levels for future testing, not to prevent tuberculosis in this study.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRS Clinical Research Services Berlin GmbH
Berlin, 13627, Germany
-
CRS Clinical Research Services Mannheim GmbH
Mannheim, 68167, Germany
-
emovis GmbH
Berlin, 10629, Germany
Conditions
Explore the condition pages connected to this study.